Brandi G - Search Results

1

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.

Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. Katoh M, et al. Among authors: brandi g. Nat Rev Clin Oncol. 2024 Apr;21(4):312-329. doi: 10.1038/s41571-024-00869-z. Epub 2024 Feb 29. Nat Rev Clin Oncol. 2024. PMID: 38424198 Review.

2

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Rizzo A, et al. Among authors: brandi g. Front Oncol. 2021 Dec 17;11:803133. doi: 10.3389/fonc.2021.803133. eCollection 2021. Front Oncol. 2021. PMID: 34976841 Free PMC article. Review.

3

Asbestos and Intrahepatic Cholangiocarcinoma.

Brandi G, Tavolari S. Brandi G, et al. Cells. 2020 Feb 12;9(2):421. doi: 10.3390/cells9020421. Cells. 2020. PMID: 32059499 Free PMC article. Review.

4

Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?

Brandi G, Tovoli F, Tavolari S. Brandi G, et al. Gastroenterology. 2023 Jan;164(1):15-18. doi: 10.1053/j.gastro.2022.10.030. Epub 2022 Nov 9. Gastroenterology. 2023. PMID: 36334819 No abstract available.

5

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.

Brandi G, Straif K, Mandrioli D, Curti S, Mattioli S, Tavolari S. Brandi G, et al. Ann Glob Health. 2022 Jun 13;88(1):41. doi: 10.5334/aogh.3660. eCollection 2022. Ann Glob Health. 2022. PMID: 35755315 Free PMC article. Review.

6

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.

Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Rizzo A, et al. Among authors: brandi g. Cancer Control. 2020 Jan-Dec;27(1):1073274820983013. doi: 10.1177/1073274820983013. Cancer Control. 2020. PMID: 33356500 Free PMC article. Review.

7

Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.

Rizzo A, Ricci AD, Tavolari S, Brandi G. Rizzo A, et al. Among authors: brandi g. Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441-452. doi: 10.21873/cgp.20203. Cancer Genomics Proteomics. 2020. PMID: 32859625 Free PMC article. Review.

8

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.

Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Rizzo A, et al. Among authors: brandi g. Cancers (Basel). 2020 Nov 4;12(11):3256. doi: 10.3390/cancers12113256. Cancers (Basel). 2020. PMID: 33158162 Free PMC article. Review.

9

Nivolumab: an investigational agent for the treatment of biliary tract cancer.

Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Di Federico A, et al. Among authors: brandi g. Expert Opin Investig Drugs. 2021 Apr;30(4):325-332. doi: 10.1080/13543784.2021.1863946. Epub 2020 Dec 23. Expert Opin Investig Drugs. 2021. PMID: 33307866 Review.

10

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies.

Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Brandi G, et al. Oncotarget. 2015 Jun 20;6(17):14744-53. doi: 10.18632/oncotarget.4539. Oncotarget. 2015. PMID: 26142706 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page